Tim Opler, Flame Biosciences co-CEO
January 11, 2023 12:48 PM ESTUpdated 05:25 PM
Startups
R&D

Flame Bio­sciences search­es for fu­ture af­ter No­var­tis flunks on canakinum­ab

Kyle LaHucik

Senior Reporter

Flame Bio­sciences de­buted with the idea that its mon­o­clon­al an­ti­body that in­hibits IL-1ß, a key cy­tokine in in­flam­ma­tion, would be ef­fec­tive at re­duc­ing can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times